Comparative Pharmacology
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus RYANODEX.
CYCLOBENZAPRINE HYDROCHLORIDE vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant